Comparison of Drug Effectiveness between PEG-IFN ?-2a and PEG-IFN ?-2b with Ribavirin for the Treatment of Korean Hepatitis C Patients

Title
Comparison of Drug Effectiveness between PEG-IFN ?-2a and PEG-IFN ?-2b with Ribavirin for the Treatment of Korean Hepatitis C Patients
Authors
정주홍
Keywords
comparisonofdrugeffectivenessbetweenpegifn2aandpegifn2bwithribavirinforthetreatmentofkoreanhepatitiscpatients
Issue Date
2012
Publisher
인하대학교
Abstract
BACKGROUND & AIMS: Pegylated interferon (peginterferon, PEG-IFN) combined ribavirin is a gold standard drug in treatment of chronic Hepatitis C (CHC). In drug utillity of the two kinds of PEG-IFN, Pegylated interferon alfa 2a (peginterferon ?-2a, PEG-IFN ?-2a) and Pegylated interferon alfa-2b (peginterferon ?-2b, PEG-IFN ?-2b), there have been controversial opinions globally and insufficient researches of Korean CHC. This retrospective comparative single center, large scaled study was conducted for the purpose to compare of antiviral effectiveness between PEG-IFN α-2a and PEG-IFN α-2b combined ribavirin as treatment in Korean CHC. Methods: In Inha University Hospital, 154 CHC patients were treated with either PEG-IFN α-2a group (group A, n = 92 (genotype 1 : 72, genotype non-1 : 20)) 180 µg/week or PEG-IFN α-2b group (group B, n = 62 (genotype 1 : 44, genotype non-1 : 18)) 1.5 µg/kg/week with concurrent ribavirin administration (800 mg/day for genotype non-1 or 1,000-1,200
Description
Ⅰ. Introduction 10 Ⅱ. Patients and Methods 12 2.1 Patients 12 2.2 Study design 12 2.3 Dose modifications 13 2.4 Assessment of efficacy and tolerability 13 2.5 Statistical analysis 14 Ⅲ. Results 16 3.1 Baseline demographics and characteristics 16 3.2 Efficacy 16 3.3 Factors related to SVR 17 3.4 Adverse Events and Tolerability 18 Ⅳ.Discussion 20 Ⅴ.Tables 26 5.1 Demographic and Baseline Disease Characteristics of the Study Patients (Table 1) 26 5.2 Virologic response (Table 2) 28 5.3 Univariate analysis of SVR (Table 3) 29 5.4 Multivariate analysis of SVR (Table 4) 32 5.5 Adverse events (AEs) (Table 5) 32 5.6 Early drug discontinuation (Table 6) 34 Ⅵ.Acknowledgement 36 Ⅶ.References 37
URI
http://dspace.inha.ac.kr/handle/10505/23469
Appears in Collections:
Medical School/College of Medicine (의학전문대학원/의과대학) > Medical Science (의학) > Theses(의학 석박사 학위논문)
Files in This Item:
24551.pdfDownload

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse